Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Reclast for postmenopausal osteoporosis treatment
The company says that, unlike oral bisphosphonate therapies that have to be taken daily, weekly or monthly, Reclast is given as a once-yearly 15-minute intravenous (IV) infusion. This
The company says that, unlike oral bisphosphonate therapies that have to be taken daily, weekly or monthly, Reclast is given as a once-yearly 15-minute intravenous (IV) infusion. This
The study is a primary treatment therapy program for men suffering from clinically localized but aggressive high-risk prostate cancer. The study began in late 2006 and will enroll
Soliris is approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can
Orphan drug designation entitles Atlanta-based Tikvah to seven years of market exclusivity for phenylbutyrate for the treatment of patients with spinal muscular atrophy (SMA). Additional incentives for orphan
The agreement expands upon an existing alliance between the companies. Under the new terms, Pharmion’s milestone payments to MethylGene could reach approximately $22 million, based on the achievement
Myriad has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to
Under the terms of the OTC license agreement, Schering-Plough is responsible for the development, manufacturing and commercialization of OTC products using Santarus’ proton pump inhibitor (PPI) technology with
The results, which have been published Annals of Neurology, are from two studies over two years designed to asses the relationship between disease activity and health-related quality-of-life (HRQoL)
“In addition to demonstrating that Neuvenge was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other
The original five-year contract was signed in August 2002, and under that contract Cangene developed and delivered vaccinia immune globulin intravenous (VIG) product to the US strategic national